These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18578076)

  • 1. Hepatitis C: the juggernaut rolls on unchecked.
    Sherman M
    Can J Gastroenterol; 2008 Apr; 22(4):355-6. PubMed ID: 18578076
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hepatitis C: a study predicts a costly future if nothing is done now].
    Perreault D
    Perspect Infirm; 2014; 11(4):14. PubMed ID: 25271350
    [No Abstract]   [Full Text] [Related]  

  • 3. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990.
    Krahn M; Wong JB; Heathcote J; Scully L; Seeff L
    Med Decis Making; 2004; 24(1):20-9. PubMed ID: 15005951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic HCV infections. A model disease for therapy, economics and social-medical aspects].
    Rossol S
    Gesundheitswesen; 2007 Mar; 69(3):146-50. PubMed ID: 17440844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease burden of chronic hepatitis C among immigrants in Canada.
    Chen W; Krahn M
    J Viral Hepat; 2015 Dec; 22(12):1043-54. PubMed ID: 26110922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C: What lies ahead and can we afford it?
    Howie H; Hutchinson SJ
    J Viral Hepat; 2004 Sep; 11 Suppl 1():28-33. PubMed ID: 15357861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort.
    Thein HH; Yi Q; Heathcote EJ; Krahn MD
    J Viral Hepat; 2009 Nov; 16(11):802-13. PubMed ID: 19413692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model.
    El Saadany S; Coyle D; Giulivi A; Afzal M
    Eur J Health Econ; 2005 Jun; 6(2):159-65. PubMed ID: 15761777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rising health and economic burden of chronic hepatitis C.
    Montella M; Crispo A; Wynn-Bellezza J; Izzo F; Grimaldi M; Ronga D
    J Hepatol; 2004 Aug; 41(2):353-4; author reply 354-5. PubMed ID: 15288490
    [No Abstract]   [Full Text] [Related]  

  • 10. Essential need for research in hepatitis C.
    McCombs JS
    J Med Econ; 2015; 18(7):512-3. PubMed ID: 25687753
    [No Abstract]   [Full Text] [Related]  

  • 11. [The burden of viral hepatitis in the Russian Federation requires reducing its progression for the long term, including chronic hepatitis C)].
    Iushchuk ND; Znoĭko OO; Iakushechkina NA; Zyrianov SK; Shut'ko SA; Belyĭ PA; Kozina AN; Chapurin SA; Churilin IuIu; Lugovskikh EA
    Ter Arkh; 2013; 85(12):79-85. PubMed ID: 24640674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
    Roebuck MC; Liberman JN
    Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply: Essential need for research in hepatitis C.
    Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
    J Med Econ; 2015; 18(7):514-5. PubMed ID: 25744591
    [No Abstract]   [Full Text] [Related]  

  • 14. Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences.
    Ward T; Gordon J; Bennett H; Webster S; Sugrue D; Jones B; Brenner M; McEwan P
    Public Health; 2016 Dec; 141():42-51. PubMed ID: 27932014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.
    Örmeci N; Malhan S; Balık İ; Ergör G; Razavi H; Robbins S
    Hepatol Int; 2017 Nov; 11(6):509-516. PubMed ID: 29027109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient time costs and out-of-pocket costs in hepatitis C.
    Federico CA; Hsu PC; Krajden M; Yoshida EM; Bremner KE; Weiss AA; Anderson FH; Krahn MD
    Liver Int; 2012 May; 32(5):815-25. PubMed ID: 22221745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.
    Krüger K; Krauth C; Rossol S; Mauss S; Boeker KHW; Müller T; Klinker H; Pathil A; Heyne R; Stahmeyer JT;
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):230-240. PubMed ID: 30325794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
    Stahmeyer JT; Rossol S; Bert F; Antoni C; Demir M; Hinrichsen H; Hüppe D; Teuber G; Wiebner B; Wedemeyer H; Krauth C
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1278-85. PubMed ID: 25144493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HIV infection: now a chronic disease].
    Katlama C
    Presse Med; 2005 Nov; 34(20 Pt 2):1561-2. PubMed ID: 16314814
    [No Abstract]   [Full Text] [Related]  

  • 20. Need for Increasing Hepatitis A Virus Vaccination Among Patients Infected With Hepatitis B Virus and Hepatitis C Virus.
    Moorman AC; Xing J; Nelson NP;
    Gastroenterology; 2018 Jun; 154(8):2015-2017. PubMed ID: 29730024
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.